Bifluranol

Research use only, not for human use.

Bifluranol (BX341) has anti-androgenic activity and has shown significant anti-prostatic activity in in vivo studies for the treatment of benign prostatic hyperplasia (BPH).

Bifluranol (BX341) is an anti-androgen.

——

The absorption, distribution and excretion of Bifluranol have been studied in mouse, rat, ferret and dog; Bifluranol is readily absorbed following oral administration, but blood concentrations of Bifluranol are low due to hepatic uptake and biliary excretion. After intravenous administration of [3H]Bifluranol to rats (200 μg/kg) and ferrets (60 μg/kg) the blood concentrations of 3H decreases rapidly for the first 2 to 3 h, with the decrease being more rapid in females ( 18 min for rat, 30 min for ferret) than males (1.0 h for rat, 1.4 h for ferret). This is followed by a much slower decline (40 h for rat, 20 h for ferret) to concentrations at 96 h of less than 15 ng Bifluranol equivalents mL-1 (rat) or 1 ng Bifluranol equivalents mL-1 (ferret).

——

Endocrinology/Hormones

Androgen Receptor (AR)

Androgen Receptor

——

——

34633-34-6

292.32

C17H18F2O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (342.09 mM; Ultrasonic )

CC[C@H]([C@H](C)c1ccc(O)c(F)c1)c1ccc(O)c(F)c1

——

(-20℃)

With Ice Pack

≥ 2 years